Holen Sie sich die Stockscreener-App
22.13
7.44%
-1.78
Handel nachbörslich:
21.98
-0.15
-0.68%
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Neurogene Inc. (NGNE) CFO sells 4,800 shares under 10b5-1 plan - Stock Titan
Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
NGNE SEC FilingsNeurogene 10-K, 10-Q, 8-K Forms - Stock Titan
Should You Buy Neurogene Inc (NGNE) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
[144] Neurogene Inc. SEC Filing - Stock Titan
Neurogene: Stock Soars On FDA Designation For Rett Gene TherapyI'd Remain Cautious - Seeking Alpha
Canaccord Genuity Initiates Coverage of Neurogene (NGNE) with Buy Recommendation - Nasdaq
Neurogene (NASDAQ:NGNE) Now Covered by Canaccord Genuity Group - MarketBeat
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
FDA grants breakthrough therapy status to Neurogene’s Rett drug - Investing.com India
Why Is Neurogene Stock Skyrocketing Friday?Neurogene (NASDAQ:NGNE) - Benzinga
Neurogene : NGNE - 24/7 Wall St.
Neurogene Inc (ticker: NGNE) shares surged 32% in pre-market trading after the company announced that its experimental therapy for rare neurological diseases has received "Breakthrough Therapy" designation from the U.S. Food and Drug Administration (F - Bitget
Neurogene Gets FDA Breakthrough Tag For NGN-401 In Rett Syndrome; Stock Up - Nasdaq
FDA grants breakthrough therapy status to Neurogene’s Rett drug By Investing.com - Investing.com Australia
Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy - TipRanks
Neurogene stock surges 30% on FDA breakthrough therapy status - Investing.com
Neurogene stock surges 30% on FDA breakthrough therapy status By Investing.com - Investing.com Australia
Neurogene Inc. wins FDA Breakthrough Therapy Designation for NGN-401 gene therapy - Traders Union
Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy - Bitget
Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome - marketscreener.com
FDA grants Breakthrough status to Neurogene (NGNE) Rett gene therapy - Stock Titan
FDA fast-tracks one-time Rett syndrome gene therapy from Neurogene - Stock Titan
Neurogene Inc. (NGNE) Stock Analysis: Exploring a Potential 184.72% Upside in the Biotech Sector - DirectorsTalk Interviews
NGNE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Neurogene Inc. (NGNE) CSO awarded 16,500 restricted stock units - Stock Titan
Neurogene (NGNE) CMO receives new stock option and RSU grants - Stock Titan
[Form 4] Neurogene Inc. Insider Trading Activity - Stock Titan
Neurogene (NGNE) grants 12,050 non-qualified stock options to director Palekar - Stock Titan
Director at Neurogene (NGNE) granted 12,050 non-qualified stock options - Stock Titan
Neurogene Inc. (NGNE): Investor Outlook With A 232% Potential Upside - DirectorsTalk Interviews
Aug Analyst Calls: What is the earnings history of Neurogene IncJuly 2025 Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Redmile discloses 9.9% Neurogene (NGNE) ownership stake via warrants and shares - Stock Titan
Is Neurogene Inc. stock near bottom after declineEarnings Overview Report & Safe Capital Growth Stock Tips - mfd.ru
Is Neurogene Inc. a potential multi baggerWeekly Profit Summary & Technical Buy Zone Confirmations - mfd.ru
How sensitive is Neurogene Inc. to inflationEntry Point & Reliable Price Breakout Alerts - mfd.ru
Can Neurogene Inc. outperform under higher oil pricesJuly 2025 Catalysts & Accurate Intraday Trade Tips - mfd.ru
How Neurogene Inc. stock reacts to oil prices2025 Key Highlights & Expert Approved Trade Ideas - mfd.ru
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit - Yahoo Finance
Aug Shorts: Whats the analyst consensus on Neurogene IncWeekly Investment Recap & Accurate Buy Signal Alerts - baoquankhu1.vn
Neurogene Inc. (NASDAQ:NGNE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
NGNE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Neurogene Inc. (NGNE) Stock Analysis: A 238% Potential Upside Awaits Investors - DirectorsTalk Interviews
Aug Catalysts: Is Neurogene Inc a potential multi bagger2025 Trading Volume Trends & AI Based Trade Execution Alerts - baoquankhu1.vn
Neurogene to Participate in Upcoming Investor Conferences - ChartMill
Rare disease biotech Neurogene to field questions at 3 investor events - Stock Titan
Neurogene announces inducement grant under Nasdaq Listing Rule - marketscreener.com
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
One new Neurogene hire gets 2,820 stock options over 4 years - stocktitan.net
Aug Fed Impact: Is Walgreens Boots Alliance Inc forming a breakout patternJuly 2025 Drop Watch & Consistent Profit Trading Strategies - baoquankhu1.vn
Jobs Data: Does Neurogene Inc have a competitive edgeWeekly Gains Report & Expert-Curated Trade Recommendations - baoquankhu1.vn
Neurogene Inc. (NGNE) Stock Analysis: A Potential 196% Upside Opportunity In Biotech - DirectorsTalk Interviews
Brokers Issue Forecasts for Neurogene FY2025 Earnings - MarketBeat
Neurogene (NASDAQ:NGNE) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Neurogene (NGNE) with Outperform Recommendation - Nasdaq
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50 - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Aug Macro: Is Neurogene Inc stock risky to hold nowQuarterly Portfolio Report & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Risk Analysis: Can Neurogene Inc outperform under higher oil pricesTrade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):